1. Home
  2. FHB vs NAMS Comparison

FHB vs NAMS Comparison

Compare FHB & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Hawaiian Inc.

FHB

First Hawaiian Inc.

HOLD

Current Price

$24.74

Market Cap

3.4B

Sector

Finance

ML Signal

HOLD

Logo NewAmsterdam Pharma Company N.V.

NAMS

NewAmsterdam Pharma Company N.V.

HOLD

Current Price

$23.44

Market Cap

2.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FHB
NAMS
Founded
1858
2019
Country
United States
Netherlands
Employees
N/A
100
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.4B
2.8B
IPO Year
2016
2022

Fundamental Metrics

Financial Performance
Metric
FHB
NAMS
Price
$24.74
$23.44
Analyst Decision
Sell
Strong Buy
Analyst Count
7
8
Target Price
$27.00
★ $46.75
AVG Volume (30 Days)
★ 1.8M
1.7M
Earning Date
04-24-2026
05-06-2026
Dividend Yield
★ 3.86%
N/A
EPS Growth
22.91
★ 32.81
EPS
★ 1.15
N/A
Revenue
★ $880,788,000.00
$22,503,000.00
Revenue This Year
$7.00
$17.96
Revenue Next Year
$3.56
$540.65
P/E Ratio
$21.70
★ N/A
Revenue Growth
★ 8.94
N/A
52 Week Low
$22.65
$21.02
52 Week High
$30.58
$42.21

Technical Indicators

Market Signals
Indicator
FHB
NAMS
Relative Strength Index (RSI) 32.49 45.44
Support Level $23.26 $21.02
Resistance Level $27.67 $28.87
Average True Range (ATR) 0.44 1.32
MACD -0.01 0.31
Stochastic Oscillator 5.09 69.89

Price Performance

Historical Comparison
FHB
NAMS

About FHB First Hawaiian Inc.

First Hawaiian Inc is a bank holding company. It provides a diversified range of banking services to consumer and commercial customers, including deposit products, lending services, and wealth management and trust services. The company offers a variety of deposit products to its customers, including checking and savings accounts and other types of deposit accounts. It provides commercial and industrial lending, including auto dealer flooring, commercial real estate, and construction lending. It also offers comprehensive consumer lending services focused on residential real estate lending, indirect auto financing, and other consumer loans. The company's segments are Retail Banking, Commercial Banking, and Treasury, and others of which key revenue is derived from Retail Banking.

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.

Share on Social Networks: